Hemab Therapeutics Holdings, Inc.
COAG
$54.94
$0.991.84%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Net Income | -97.80% | -48.22% | |||
| Total Depreciation and Amortization | -2.60% | -2.67% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 210.17% | -15.16% | |||
| Change in Net Operating Assets | 124.01% | -73.70% | |||
| Cash from Operations | -47.64% | -65.61% | |||
| Capital Expenditure | -- | -600.00% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -599.55% | -163.22% | |||
| Cash from Investing | -599.66% | -164.38% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | 100.00% | -58.62% | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | 1,058,696.67% | -1,486.21% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 2,954.34% | -100.01% | |||